Skip to main content


Table 1 Translocation regions studied

From: Translocation junctions in TCF3-PBX1 acute lymphoblastic leukemia/lymphoma cluster near transposable elements

Genetic abnormality Clinical entity* Rearrangement Junctions‡
TCF3-PBX1 Pre-B/B-ALL t(1;19)(q23;p13.3) 60
BCR-ABL1 CML t(9;22)(q34;q11) 67
t-MLL Therapy AML t(9;11)(q22;q23) 26
MLL Primary ALL and AML t(4;11)(q21;q23) 424
   t(9;11)(q22;q23) 24
ETV6-RUNX1 Pre-B/B-ALL t(12;21)(p12;q22) 105
RUNX1-RUNX1T1 AML t(8;21)(q22;q22) 132
MYC-IGH Sporadic BL t(8;14)(q24;q32) 178
BCL6-IGH Mature B lymphomas t(3;14)(q27;q32) 52
SCL-TCRA Pre-T/T ALL t(1;14)(q32;q11) 48
LMO2-TCRA Pre-T/T ALL t(11;14)(q13;q11) 58
Total    1174
  1. TCF3: transcription factor 3; PBX1: pre B-cell leukemia transcription factor 1; BCR: breakpoint cluster region; ABL1: Abelson murine leukemia viral oncogene homolog 1; MLL: myeloid/lymphoid or mixed lineage leukemia gene; ETV6: ets variant gene 6; RUNX1: runt-related transcription factor 1; RUNX1T1: runt-related transcription factor 1 translocated to, 1; MYC: v-myc avian myelocytomatosis viral oncogene homolog; IGH: IgG heavy chain locus; BCL6: B-cell lymphoma 6; SCL: stem cell leukemia hematopoietic transcription factor; TCRA: T-cell antigen receptor, alpha subunit; LMO2: lim domain only 2, t: therapy related.
  2. *Distinct hematolymphoid neoplasms according to the World Health Organization classification; Pre-B/B-ALL: B lymphoblastic leukemia/lymphoma; CML: chronic myelogenous leukemia; Therapy AML: therapy-related acute myeloid leukemia; sporadic BL: Burkitt lymphoma; Pre-T/T-ALL: T lymphoblastic leukemia/lymphoma.
  3. ‡Number of translocation junctions examined.